EN DE
Watch Shine-On BioMedical Co.,Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Shine-On BioMedical Co.,Ltd. (6926) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Shine-On BioMedical Co.,Ltd. stock TWD 17.90, price TWD 58.90, that is 69.6% below the price, quality 46 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006926009

SO Shine-On BioMedical Co.,Ltd. logo Thin data Nov 5, 2026

Shine-On BioMedical Co.,Ltd.

6926 · TWO
Weakest Setup

Our calculation puts a fair price 70% below what the stock costs today.

Quality 46/100
Fair value 17.90 TWD · Strongly overvalued
Weak Growth
Negative free cash flow
Trails peers (2/7)
Narrow moat 5/100 · thin data
Thin data
Watch Shine-On BioMedical Co.,Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

71.30 TWD 55.50 TWD Fair Value 17.90 TWD Dec 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.

How to read this chart

11‑month range 55.50 TWD – 71.30 TWD · fair‑value band 11.81 TWD – 22.37 TWD · the 58.90 TWD price screens above the 17.90 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.

Follow Shine-On BioMedical Co. in your weekly email

Every Wednesday you see whether Shine-On BioMedical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Shine-On BioMedical Co.,Ltd. research, develops, and manufactures anti-cancer related drug products.

Show moreShow less

It also develops antibody anticancer drugs, such as exosome anti-cancer drugs, that includes SOB101 and SOB102; SOB201 for engineered multi-target exosomes; SOA101, a dual immune checkpoint T cell adapter antibody; and SOA201, a trispecific adapter immune cell antibody.

Shine-On BioMedical Co.,Ltd. was founded in 2011 and is based in Taichung, Taiwan.

Stock analysis

Shine-On BioMedical Co.,Ltd. (6926) currently trades at 58.90 TWD, while our model-based Fair Value estimate is 17.90 TWD, 70% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 11.81 TWD (bear) to 22.37 TWD (bull), the price of 58.90 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Shine-On BioMedical Co.,Ltd. reported revenue of 30.0M TWD in FY2025 versus 0 TWD in FY2021. Reported net income was −110M TWD in FY2025.

Key figures

Market cap 2.9B TWD (≈ $89.3M) Micro · P/S ratio 65.1 · EPS (TTM) −3.64 TWD · Return on equity −20.6% · Return on assets (EBIT) −6.8% (5-year average) · Operating margin −592% · Revenue (TTM) 50.6M TWD · Free cash flow −116M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (low confidence).

What moves the price

The share trades about 17% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −70%, 6926 screens richer than that median.

Fair Value models

Bear 11.81 TWD Fair Value 17.90 TWD Bull 22.37 TWD
Price 58.90 TWD · Downside -69.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 11.81 TWD 17.90 TWD 22.37 TWD 52
All 1 models by family
Asset-Based
NCAV (Graham) 11.81 TWD 17.90 TWD 22.37 TWD 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 46/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 56
Are margins and returns getting better?
Cashflow 12
Do the profits arrive as real cash?
Financial strength 79
Debt, balance sheet and risk of trouble
Investment 97
Does it invest with discipline instead of growing at any price?
Low Volatility 87
How calm the share price moves, does not count
Price momentum 34
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 19
Distance to the 52-week high, does not count
New shares 66
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6926 screens overvalued: fair value 70% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Shine-On BioMedical Co.,Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 559 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 46 · Above median
Fair Value upside −69.6% · Below median
Profitability
Return on assets −11.6% · Below median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.23× · Pricier than median
P/S (12 months) 57.95× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 6926
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 6926
Samsung Biologics Co 207940 1,510,000 KRW 1,667,600 KRW +10% vs 6926
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 6926
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 6926
WuXi Biologics (Cayman) Inc 2269 HK$48.92 HK$52.38 +7% vs 6926
argenx SE ARGX $927.21 $908.40 −2% vs 6926
CSL Limited CSL A$200.77 A$183.04 −9% vs 6926
Celltrion, Inc 068270 210,000 KRW 74,945 KRW −64% vs 6926
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 6926

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shine-On BioMedical Co.,Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Shine-On BioMedical Co.,Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/6926

Frequently asked questions

Is Shine-On BioMedical Co.,Ltd. (6926) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 17.90 TWD versus a price of 58.90 TWD, about 70% lower (overvalued).
What is the fair value of 6926?
Our model-based fair value for Shine-On BioMedical Co.,Ltd. is 17.90 TWD (as of Nov 5, 2026), built from audited fundamentals. The current price: 58.90 TWD.
What is the quality score of 6926?
Shine-On BioMedical Co.,Ltd. has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shine-On BioMedical Co.,Ltd. (6926)?
Our model-based price target is the fair value of 17.90 TWD (as of Nov 5, 2026) from 1 valuation models. Cautious scenario 11.81 TWD, optimistic scenario 22.37 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Shine-On BioMedical Co.,Ltd. stock forecast for 2026?
Our models put fair value at 17.90 TWD, about 70% lower versus a price of 58.90 TWD (overvalued). Cautious scenario 11.81 TWD, optimistic scenario 22.37 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Shine-On BioMedical Co.,Ltd. (6926)?
Shine-On BioMedical Co.,Ltd. reported trailing-twelve-month revenue of about 50.6M TWD (latest available figure, as of Nov 5, 2026).
What is the intrinsic value of Shine-On BioMedical Co.,Ltd. (6926)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shine-On BioMedical Co.,Ltd. it is 17.90 TWD per share (as of Nov 5, 2026), against a price of 58.90 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Shine-On BioMedical Co.,Ltd. stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 6926 trades above its calculated fair value: price 58.90 TWD, fair value 17.90 TWD, a gap of about −70% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6926?
No. The price is what the market pays today (58.90 TWD); the fair value is what the company's own numbers justify (17.90 TWD). For Shine-On BioMedical Co.,Ltd. the two are 41.00 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Shine-On BioMedical Co.,Ltd. worth?
The market values Shine-On BioMedical Co.,Ltd. at about 2.9B TWD (market capitalisation, as of Nov 5, 2026). Per share that is 58.90 TWD; our models calculate a fair value of 17.90 TWD per share.
What do the bullish and bearish scenarios say about 6926?
Our models span a range for Shine-On BioMedical Co.,Ltd.: cautious scenario 11.81 TWD, base 17.90 TWD, optimistic 22.37 TWD per share (as of Nov 5, 2026, price 58.90 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Shine-On BioMedical Co.,Ltd. (6926)?
Balance-sheet figures for Shine-On BioMedical Co.,Ltd. (as of Nov 5, 2026): return on equity −20.6%. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 6926 from its 52-week high?
Shine-On BioMedical Co.,Ltd. trades at 58.90 TWD, about 17% below its 52-week high of 71.30 TWD and 6% above the low of 55.50 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 17.90 TWD is for.
Which stocks are comparable to Shine-On BioMedical Co.,Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shine-On BioMedical Co.,Ltd. stock attractive at the current price?
The data as of Nov 5, 2026: price 58.90 TWD, calculated fair value 17.90 TWD (−70%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6926 calculated?
We run Shine-On BioMedical Co.,Ltd. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 17.90 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Shine-On BioMedical Co.,Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shine-On BioMedical Co.,Ltd. (6926)?
The closing price on Nov 9, 2026 was 58.90 TWD. Our model-based fair value is 17.90 TWD, about 70% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shine-On BioMedical Co.,Ltd. right now?
The price sits above even our optimistic bull case (22.37 TWD). The favourable scenario is already priced in. Weak quality (46/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (11.81 TWD to 22.37 TWD) leaves room in how you read the outcome.

Key figures of Shine-On BioMedical Co.,Ltd.

How large is the market capitalisation of Shine-On BioMedical Co.,Ltd. (6926)?
The market capitalisation of Shine-On BioMedical Co.,Ltd. is 2.9B TWD (≈ $89.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shine-On BioMedical Co.,Ltd. (6926)?
The price-to-sales ratio of Shine-On BioMedical Co.,Ltd. is 65.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shine-On BioMedical Co.,Ltd. (6926)?
Earnings per share at Shine-On BioMedical Co.,Ltd. are −3.64 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Shine-On BioMedical Co.,Ltd. (6926)?
The return on equity (ROE) of Shine-On BioMedical Co.,Ltd. is −20.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shine-On BioMedical Co.,Ltd. (6926)?
On an EBIT basis the return on assets of Shine-On BioMedical Co.,Ltd. is −6.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shine-On BioMedical Co.,Ltd. (6926)?
The operating margin of Shine-On BioMedical Co.,Ltd. is −592% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Shine-On BioMedical Co.,Ltd. (6926) generate?
The free cash flow of Shine-On BioMedical Co.,Ltd. is −116M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Shine-On BioMedical Co.,Ltd. (6926) hold?
Shine-On BioMedical Co.,Ltd. holds more cash than debt, 42.1M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Shine-On BioMedical Co.,Ltd. in the live analysis

One click puts Shine-On BioMedical Co.,Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.